F8 and hemophilia A: The most challenging complication associated with FVIII replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level <1%) HA patients and are a serious hindrance to the effective management of hemophilia A (1, 2).